Coherus BioSciences’ (CHRS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a $7.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued research reports about the stock. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Robert W. Baird upped their price objective on Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $5.38.

Coherus BioSciences Price Performance

CHRS opened at $1.28 on Thursday. The company has a market capitalization of $147.47 million, a P/E ratio of -16.00 and a beta of 0.82. The firm’s fifty day moving average price is $1.42 and its two-hundred day moving average price is $1.27. Coherus BioSciences has a fifty-two week low of $0.66 and a fifty-two week high of $2.87.

Institutional Trading of Coherus BioSciences

Hedge funds have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of Coherus BioSciences by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 2,565,145 shares of the biotechnology company’s stock worth $2,668,000 after acquiring an additional 182,914 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Coherus BioSciences by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 964,327 shares of the biotechnology company’s stock valued at $1,003,000 after purchasing an additional 116,217 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in Coherus BioSciences by 344.1% in the third quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock worth $967,000 after purchasing an additional 720,672 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Coherus BioSciences during the second quarter worth $1,246,000. Finally, XTX Topco Ltd increased its stake in shares of Coherus BioSciences by 74.5% in the third quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 202,084 shares in the last quarter. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.